Scientists test First-Ever vaccine against dangerous group b strep in seniors
NCT ID NCT05782179
Summary
This study tested a new vaccine designed to protect older adults from Group B Streptococcus (GBS) infections. Researchers gave three doses of the experimental vaccine or a placebo to 90 healthy, obese, or diabetic participants aged 55 to 75. The main goal was to check if the vaccine was safe and if it triggered a strong immune response that could fight the bacteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROUP B STREPTOCOCCAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC) department
Ghent, 9000, Belgium
Conditions
Explore the condition pages connected to this study.